Related Experiment Video
Updated: May 1, 2026

Constitutive and Inducible Systems for Genetic In Vivo Modification of Mouse Hepatocytes Using Hydrodynamic Tail Vein Injection
Published on: February 2, 2018
Interferon-gamma gene polymorphism +874 (a/t) in Chinese children with Henoch-Schonlein purpura
Hui Xu1, Wei Li2, Haidong Fu3
1Department of Clinical Laboratory, Children's Hospital of Zhejiang University School of Medicine, Hangzhou, P.R. China. xuh32323@163.com.
Abstract:
The aim of this study was to investigate the possible influence of Interferon-gamma (IFN-γ) gene polymorphism +874 (A/T) (rs2430561) in the susceptibility and renal complications of patients with Henoch-Schonlein purpura (HSP). We also studied the effects of IFN-γ allelic variation on serum levels of pro-and anti-inflammatory cytokines in HSP patients. The study population comprised 97 patients suffering from HSP and 97 control participants. Patients and controls were genotyped for a single nucleotide polymorphism +874 (A/T) in the first intron of the IFN-γ gene by the TaqMan PCR method. Frequencies of individuals with IFN-γ +874 AA, AT and TT genotypes were 77.3%, 21.6% and 1% in HSP patients and 79.4%, 17.5% and 3.1% in controls, respectively. The frequency of the AA genotype in HSP patients with nephritis was slightly higher (83.3%) than in HSP patients without nephritis (73.8%). The allele A occurred more commonly in HSP patients with nephritis (92%) than in HSP patients without nephritis (86%), but these differences were not statistically significant (p= 0.469 and p= 0.244, respectively). In addition, significant difference in serum IL-10 levels between IFN-γ +874 different genotype groups was found. Our results do not support a role for IFN-γ gene polymorphism +874 (A/T) in the susceptibility to HSP and allelic variation at IFN-γ +874 locus had no effect on serum levels of cytokines in patients with HSP except for IL-10.
Related Concept Videos
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Single Nucleotide Polymorphisms-SNPs
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

